PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

NCT04789434 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse
Transplantation
Chemotherapy

Interventions

DRUG: PD-1 Inhibitor Tislelizumab maintenance therapy

Sponsor

Ruijin Hospital